The European Medicines Agency (EMA) has not received the necessary data for the clinical trials of the Russian Sputnik V vaccine and has postponed its approval until at least September.
The approval of the Russian Sputnik V vaccine against covid-19 by the European Union will be delayed after the June 10 deadline, limiting the prospects of including the Russian drug in the European vaccination campaign.
The Russian Direct Investment Fund (RDIF) responsible for the commercial exploitation of the vaccine announced that the evaluation of Sputnik V is in progress.
Slovakia is the second European Union country after Hungary to start vaccination with Sputnik V this month, despite the lack of EMA approval.
Initially, the EMA was to approve the Russian vaccine in May or June if the conditions required by the European authorities were met.